{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"100"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"100"}]}],"title":"1 year post-MLA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"Score ranges from 100% to 10%. A higher score indicates that the patient has a more normal quality of life.","groups":[{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG000","title":"Patient 1: Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG001","title":"Patient 2: Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG002","title":"Patient 3: Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG003","title":"Patient 4: Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"OG004","title":"Patient 5: Arm A (MRI-guided Laser Ablation)"}],"paramType":"NUMBER","populationDescription":"This data was not collected on the patient from Arm B.","reportingStatus":"POSTED","timeFrame":"At 1 year post-MLA","title":"Change in Quality of Life as Measured by Karnofsky or Lansky Performance Status","type":"SECONDARY","unitOfMeasure":"score on a scale"}